四川地区30例重型新型冠状病毒肺炎患者肝损伤的临床特征
该回顾性研究纳入2020年1月21日至2月24日成都市公共卫生临床医疗中心收治的30例重型COVID-19患者,收集入ICU 1周内人口学、临床表现及肝功能变化。结果显示ALT、AST、TBil、PT不同程度升高,ALB降低。按是否服用洛匹那韦/利托那韦分组,服药组7天内ALT异常率54% vs 33%、AST 38% vs 33%、TBil 8% vs 0%,差异均无统计学意义。按剂量分常规剂量组(500 mg 每日两次,n=19)与减量组(250 mg 每日两次,n=5),减量组入ICU第2天ALB(33.3±2.0 vs 37.5±4.0 g/L)和TBil(6.3±3.3 vs 11.3±4.8 μmol/L)显著低于常规剂量组(均P<0.05)。作者认为治疗中应注意避免使用加重肝损伤的药物,如无替代药物可适当考虑保肝治疗。
要点
- 30例重型COVID-19患者入ICU 1周内ALT、AST、TBil、PT不同程度升高,ALB降低,提示早期肝损伤明显且恢复较慢。
- 服用洛匹那韦/利托那韦者7天内ALT异常率54% vs 未服用者33%,AST 38% vs 33%,TBil 8% vs 0%,差异均无统计学意义(均P>0.05)。
- 洛匹那韦/利托那韦减量组(250 mg 每日两次,n=5)入ICU第2天ALB 33.3±2.0 g/L、TBil 6.3±3.3 μmol/L,均显著低于常规剂量组(500 mg 每日两次,n=19)的37.5±4.0 g/L、11.3±4.8 μmol/L(均P<0.05)。
- 重型患者以老年男性多见(60.0%),中位年龄61(47,79)岁,80岁及以上占23.3%,主要表现为发热(96.7%)、咳嗽(80.0%)、呼吸困难(66.7%)。
- 作者认为治疗中应注意避免使用可加重肝损伤的药物,如无替代药物可适当考虑保肝治疗。
适用人群与场景
- 2020年1月21日至2月24日成都市公共卫生临床医疗中心收治的重型COVID-19患者,临床资料完整者30例。
- 研究对象为入住ICU的重型COVID-19患者,分析入ICU 1周内肝功能变化。
处置流程与药物剂量
- 洛匹那韦/利托那韦常规剂量组:500 mg,每日两次,n=19。
- 洛匹那韦/利托那韦减量组:250 mg,每日两次,n=5。
- 作者认为治疗中应注意避免使用可加重肝损伤的药物;如无替代药物,可适当考虑保肝治疗。
研究设计与关键结果
- 回顾性研究,纳入30例重型COVID-19患者,老年男性多见(60.0%),中位年龄61(47,79)岁,80岁及以上占23.3%。
- 临床表现以发热(96.7%)、咳嗽(80.0%)、呼吸困难(66.7%)为主。
- 入ICU 1周内ALT、AST、TBil、PT不同程度升高,ALB降低。
- 按是否服用洛匹那韦/利托那韦分组:服药组7天ALT异常率54% vs 未服药组33%,AST异常率38% vs 33%,TBil异常率8% vs 0%,差异均无统计学意义(均P>0.05)。
- 按剂量分组:减量组(250 mg 每日两次,n=5)入ICU第2天ALB 33.3±2.0 g/L、TBil 6.3±3.3 μmol/L,均显著低于常规剂量组(500 mg 每日两次,n=19)的37.5±4.0 g/L、11.3±4.8 μmol/L(均P<0.05)。
证据类型、等级与局限
- 证据类型:回顾性临床研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对重型COVID-19患者应监测入ICU 1周内肝功能(ALT、AST、TBil、PT、ALB),警惕早期肝损伤及恢复缓慢。
- 使用洛匹那韦/利托那韦时需关注肝损伤,减量方案(250 mg 每日两次)在本研究中显示入ICU第2天ALB、TBil显著低于常规剂量组(500 mg 每日两次),但样本量小(减量组n=5),作者认为如无替代药物可适当考虑保肝治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To describe the characteristics of liver damage in severe coronavirus disease 2019 (COVID-19) patients in Sichuan area and the effect of antiviral drugs on liver function.
METHODS: The clinical data of severe COVID-19 patients admitted to Chengdu Public Health Clinical Medical Center from January 21 to February 24, 2020 were retrospectively collected, including demographic data, clinical manifestations and liver function changes within 1 week after admission to intensive care unit (ICU). The changes of liver function during the course of disease in severe COVID-19 patients were analyzed and summarized, and group analysis was performed.
RESULTS: A total of 30 COVID-19 patients with complete clinical data were enrolled. The incidence of severe COVID-19 in elderly men was higher (60.0%), with median age of 61 (47, 79) years old, and those aged 80 or above accounted for 23.3%. The severe COVID-19 patients mainly presented with respiratory symptoms such as fever (96.7%), cough (80.0%) and dyspnea (66.7%). The alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and prothrombin time (PT) of 30 patients were increased to various degrees within 1 week after ICU admission, and albumin (ALB) was decreased. (1) The patients were divided into two groups according to whether to take lopinavir/ritonavir (kaletra). It was shown that the incidence of liver dysfunction in patients taking kaletra was significantly higher than those who did not take kaletra (7-day abnormal rate of ALT was 54% vs. 33%, the abnormal rate of AST was 38% vs. 33%, the abnormal rate of TBil was 8% vs. 0%), but there were no statistical differences (all P > 0.05). (2) The patients were divided into normal dose group (500 mg, twice a day, n = 19) and reduced dose group (250 mg, twice a day, n = 5) according to the dosage of kaletra. It was shown that patients taking low-dose kaletra had a smaller effect on liver function within 1 week after ICU admission than those receiving normal dosage, and ALB, TBil in the reduced dose group were significantly lower than those in the normal dose group on the 2nd day after ICU admission [ALB (g/L): 33.3±2.0 vs. 37.5±4.0, TBil (μmol/L): 6.3±3.3 vs. 11.3±4.8, both P < 0.05].
CONCLUSIONS: Severe COVID-19 patients in Sichuan area suffered obvious liver damage in the early course of the disease and have a slower recovery. It is important to pay attention to avoid using drugs that can aggravate liver damage while treating the disease. If there is no alternative drug, liver protection treatment should be considered appropriately.
参考来源
- Li T, Deng C, Du Q, et al. [Clinical characteristics of liver damage in 30 patients with severe coronavirus disease 2019 in Sichuan area]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32912404. doi:10.3760/cma.j.cn121430-20200513-00656
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。